Key Points
- KalVista Pharmaceuticals CEO Benjamin Palleiko sold 3,322 shares on May 12 at an average price of $26.71, totaling about $88,731. The filing says the sale was to cover tax withholding obligations tied to vested equity awards.
- After the transaction, Palleiko still owned 466,375 shares valued at about $12.46 million, a modest 0.71% decrease in his position.
- The stock has recently surged near its 52-week high of $26.85, while analysts currently rate KalVista a Hold overall with an average target price of $30.60.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin Palleiko sold 3,322 shares of the business's stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $26.71, for a total transaction of $88,730.62. Following the transaction, the chief executive officer owned 466,375 shares in the company, valued at $12,456,876.25. This represents a 0.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
KalVista Pharmaceuticals Price Performance
Shares of NASDAQ KALV opened at $26.80 on Thursday. KalVista Pharmaceuticals, Inc. has a 1 year low of $9.83 and a 1 year high of $26.85. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The company's 50-day moving average is $19.97 and its 200 day moving average is $16.54. The stock has a market capitalization of $1.37 billion, a P/E ratio of -6.78 and a beta of -0.12.
Analyst Upgrades and Downgrades
A number of equities research analysts have weighed in on the stock. Citizens Jmp cut shares of KalVista Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 29th. JonesTrading cut shares of KalVista Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 30th. HC Wainwright cut shares of KalVista Pharmaceuticals from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $37.00 to $27.00 in a report on Friday, May 1st. Wall Street Zen cut shares of KalVista Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, April 21st. Finally, Stifel Nicolaus upped their price objective on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a "buy" rating in a report on Thursday, March 26th. Three analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, KalVista Pharmaceuticals currently has a consensus rating of "Hold" and an average target price of $30.60.
View Our Latest Research Report on KalVista Pharmaceuticals
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the company. Parallel Advisors LLC lifted its stake in shares of KalVista Pharmaceuticals by 45.8% in the first quarter. Parallel Advisors LLC now owns 1,876 shares of the specialty pharmaceutical company's stock worth $38,000 after buying an additional 589 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in shares of KalVista Pharmaceuticals by 47.0% in the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company's stock worth $46,000 after buying an additional 1,292 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of KalVista Pharmaceuticals in the third quarter worth approximately $55,000. Wolverine Asset Management LLC bought a new position in shares of KalVista Pharmaceuticals in the third quarter worth approximately $57,000. Finally, Truvestments Capital LLC lifted its stake in shares of KalVista Pharmaceuticals by 253.8% in the fourth quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company's stock worth $76,000 after buying an additional 3,360 shares in the last quarter.
KalVista Pharmaceuticals Company Profile
(
Get Free Report)
KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm's scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista's approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.
The company's lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
